Multi-institutional observational research of therapeutic evaluation with minimal residual disease(MRD) after consolidation for multiple myeloma

Multi-institutional observational research of therapeutic evaluation with minimal residual disease(MRD) after consolidation for multiple myeloma - OCHA-MRD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032970

Enrollment

Registered

2018-06-14

Start date

2018-06-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Days 90 to 180 after first and/or tandem autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. 2. No previous consolidation and maintenance therapy. 3. Patient who is planed Consolidation therapy. 4. PR after autologous stem cell transplantation. 5. Patient who provided written consents for this study.

Exclusion criteria

Exclusion criteria: Patient who is judged to be medically unfit by physician.

Design outcomes

Primary

Measure	Time frame
The MRD negative rate by evaluating multiparameter flow cytometry(MFC) after consolidation therapy.	—

Countries

Japan

Contacts

Public ContactDaisuke Kudo

Tokyo-kita Medical Center Department of hematology

daisukekud@jadecom.jp03-5963-3311

Outcome results